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Abstract 
This Major Qualifying Project looks at the potential the CircumBlator, a novel cardiac 
ablation device, in various markets to develop a go to market strategy for the product. Market 
and Regulatory research was conducted utilizing sources such as the Atrial Fibrillation 
Association and the White Book from the European Society of Cardiology. From the research, 
the United States (US) and the European Union (EU) were seen as ideal markets for initial entry. 
Guidelines for conducting research and developing decisions were also provided for future teams 
to conduct similar projects or continue this one. 
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Executive Summary 
Arrhythmia is a condition that plagues its sufferers with either episodes or an unfortunate 
consistence of irregular heartbeats. The most common form of this condition is known as Atrial 
Fibrillation and occurs due to a malfunction in the transference of electrical signals in the nerves 
near the heart. This ailment is found, on average, to affect about one percent of a given populace 
with the majority of those suffering being over the age of sixty five. Many treatments are 
conducted to attempt to remedy this condition, including drug and rhythm control. What has 
been found to be a better solution that rarely leads to complications is known as a rate control 
treatment, keeping the heart rate within an acceptable range. One of the most common 
procedures to control the heart rate is cardiac ablation. This procedure essentially scars and 
deactivates the heart tissue that conducts these malfunctioning electrical signals. 
 Ablacor Medical Corporation has developed a device to make cardiac ablation a simpler 
and more permanent solution. The CircumBlator™ is a device that anchors on to the entry for the 
pulmonary vein. Using an electrode pad and ablation umbrella, the CircumBlator™ will scar the 
appropriate tissue while closely monitoring its force on the tissue and the temperature of the 
burn. This project aims to determine an initial market as consideration for this product by 
researching and analyzing: 
 Market data comprised of condition prevalence and treatment information. 
 Regulatory research to understand procedural requirements. 
 The combination of the both to find a suitable market in both potential acceptance and 
overall adoption of medical devices. 
 The reimbursement process of a selected market’s insurance environment. 
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Using this data, the team aims to create a system of elimination and ordering to find the 
most ideal markets for consideration. Beginning with a fairly large list of countries and regions, 
the team researched: 
 Atrial Fibrillation prevalence data, such as number of cases, cases per capita, etc. 
 The level of adoption of cardiac ablation through number of clinics ablating and 
number of ablations conducted per year. 
 The percent market share the region holds globally in medical devices. 
 The annual investment in medical devices. 
From this information, the team developed a decision flow and organized the most ideal 
markets into strategic groups. Then, two countries and one region were picked from these groups 
based on market strength and potential regulatory excellence. The focus of the regulatory 
research and analysis at this point was to find a market with the quickest and least costly 
regulatory process, while still granting benefits. The major benefit found is that many regulatory 
approvals are accepted internationally, often in lieu of a separate regulatory process. This factor 
weighed heavily on a decision for an initial market. 
Once a market was decided upon, the rest of the efforts involved what entering the 
market would specifically entail. This research mainly involved looking at the reimbursement 
process for new and current medical devices to understand what the next steps would be beyond 
regulatory approval. The final step of the project was a guide that future teams can use to 
undergo the same process. However, this guideline will provide extra focus for the team’s 
research as well as advice based on the experience of this decision process. 
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1 Introduction 
 This Major Qualifying Project entailed conducting a feasibility analysis on several 
countries and regions in order to determine a consideration for an initial market. This market is 
the recommendation for entry for a medical device treating a cardiovascular condition known as 
Atrial Fibrillation. By applying previous knowledge of market planning and other aspects of 
business in a group environment, the team aimed to also use knowledge of the biomedical 
industry and government regulations to produce the most opportune decision. The team then 
analyzed the methods taken to come to a conclusion and produced a set of guidelines that can be 
followed to make additional decisions. 
 Fulfilling the requirements for a management, management engineering, and biomedical 
engineering focus, this project aided an established business further its goals utilizing knowledge 
gathered from previous marketing and business classes. The project focused on the success of a 
biomedical device on a global scale, applying research techniques to uncover regulatory 
information and reimbursement information used to estimate sales projections. This report was 
also used as a basis for presentations and a poster design showcasing the team’s methodology 
and results. 
 The team assisted Ablacor™, a biomedical company aiming to bring an innovative 
cardiac ablation device to market, by conducting research into the market and regulatory aspects 
of different countries and regions. After making an initial decision, the team researched the 
reimbursement process in the select country within the selected region to aid in the estimation of 
sales projections. To conclude the project, the team supplied a guideline for future teams to 
complete similar projects, including focal points for each of the stages that the project 
underwent. 
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1-1 Mission Statement 
The mission of this Major Qualifying Project is to supply Ablacor with a framework with 
which it can best determine the most suitable foreign markets for entry, and to propose an entry 
strategy for one country or region categorized as an ideal market.  
1-2 Objectives 
• To research Atrial Fibrillation and treatment data across selected countries and regions. 
• To research the various regulations attributed to implementing a biomedical device in a foreign 
market. 
• To determine, based on the research, the most suitable markets for initial consideration for 
entry. 
• To develop a model to assess the feasibility of entering a foreign market. 
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2 Background 
2-1 Mechanics of Atrial Fibrillation 
 Atrial Fibrillation (AF) is the most common type of cardiac arrhythmia, or irregular heartbeat. 
Arrhythmias manifest in a variety of fashions causing the heart to beat too quickly, too slowly, or 
irregularly and are caused by irregular electrical signals that control heartbeat. In a normal beating heart, 
these electrical impulses start at the top of the heart and move downwards. The signals originate in the 
sinoatrial (SA) node which is located in the right atrium. The SA node modifies the pace of impulses 
depending on the level of activity. Once the signal has left the SA node, it spreads through both atria 
causing them to contract and pump blood into the ventricles. The electrical signal then moves to the 
atrioventricular (AV) node, between the atria and the ventricles, which passes the impulse onto the 
ventricles. The AV node serves as the only connection for impulses between the atria and the ventricles; 
in addition, it slows electrical signals to allow the ventricles to fill.  The resulting impulse from the AV 
node causes the ventricles to contract and pump blood to the rest of the body. 
 In patients with AF, the electrical impulses start in the atria or pulmonary veins instead of the SA 
node. Impulses from across the atria move down the heart in a disorganized manner causing the atria to 
contract irregularly. As impulses move to the AV node, they arrive rapidly and irregularly. The AV node 
maintains its ability to control the number of impulses that pass to the ventricles at a given time; however 
because the impulses arrive so closely together more are able to pass in the same period of time. This 
causes the ventricles to beat at a higher rate than in normal. Though the ventricles beat faster than normal, 
their rhythm is slower than the atria due to the AV nodes control of impulses.  
  Irregular contractions in the atria and ventricles prevent the atria from efficiently pumping blood 
into the ventricles. The increased contraction of the atria causes only some of the blood to move from the 
atria into the ventricles. As a result the remaining blood pools in the atria which can lead to blood clots. 
These clots can travel to the brain and increase the risk of strokes (“What is Atrial Fibrillation?”). The 
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irregular contraction of the ventricles does not allow for the efficient pumping of blood throughout the 
body and can lead to heart failure.  
2-2 Types of AF 
 There are three main categories of AF depending on the frequency of incidents and response to 
treatments, paroxysmal, persistent, and permanent. Paroxysmal AF incidents start suddenly and end 
without medical intervention. The severity of symptoms can vary from very mild to severe and incident 
lengths last less than one week (Khoo, Krishnamoorthy, and Lip).  Patients with persistent AF have 
irregular heartbeats that last for longer than one week. Persistent AF symptoms stop on their own or with 
the aid of common treatment methods. Finally, permanent AF occurs when regular heart rhythms cannot 
be restored with treatment. Both paroxysmal and persistent AF can evolve into permanent AF (“What is 
Atrial Fibrillation?”). 
2-3 Prevalence 
 Research into AF has increased in recent years; however prevalence data is still largely 
inconclusive. When looking at data for AF within the US alone, different organizations and scholarly 
articles present varying numbers. Many of the numbers are general estimates as many people living with 
AF are unaware of the condition and symptoms until they experience a stroke or heart failure. In addition, 
there is a low representation of patients with paroxysmal AF as their symptoms vary in severity and 
length (Chugh et al.).  
 Though the exact numbers may be unclear, many studies conducted over several years have 
found that the incidence of AF in the US is approximately one percent of the adult population (Naccarelli 
et al.). The prevalence of AF greatly increases with age, and has been found to affect between 5% and 9% 
of individuals over the age of 60 (Chugh et al.). Of all those affected with AF it is estimated that 84% are 
over the age of 65 (Chugh et al.). The overall prevalence of atrial fibrillation is expected to increase 
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dramatically over the next decades with estimates as high as 7.56 million in the US alone by 2050 
(Naccarelli et al.). 
2-4 Treatment Options 
 There are several treatment options for atrial fibrillation depending on the frequency and the 
severity of symptoms. If a patient’s AF was caused by another condition then the primary course of action 
is to treat the trigger condition. Outside of treating conditions that trigger AF, there are two main courses 
of treatment, rhythm treatments and rate treatments. Rhythm treatments aim to set the heart back to 
normal sinus rhythm, or regular heartbeat, while rate treatments aim to slow the heart rate to within 
normal limits.  
Rhythm control treatments use cardioversion to restore the heart to its regular rhythm. 
Cardioversion can be accomplished in either of two main methods, through medication or electrically 
(Gutierrez and Blanchard).  When using medicine for cardioversion, it is important to consider all medical 
conditions that may be affected by the treatment. It is common for doctors to require continuous 
monitoring in a hospital setting to begin in order to insure that there are no negative results 
(“Treatments”). Maintaining a normal sinus rhythm with medicine can be difficult due to negative side-
effects and the increased risk of ventricular arrhythmias (Gutierrez and Blanchard). In addition to 
medication, cardioversion can also be done with electrical procedures. Electrical cardioversion uses an 
electrical shock to temporarily stop the heart and return it to normal rhythm after the procedure. Though 
rhythm control seems like the better and potentially less invasive option, it is often used as the last course 
of action in patients after rate treatments have been done.  Rhythm control treatments lead to more 
hospitalizations, and more serious negative side effects (Gutierrez and Blanchard). 
Rate control is the primary means of controlling AF as it has fewer adverse effects than rhythm 
control. Rate control treatments aim to reduce the ventricular heart rate to between 60 and 80 beats per 
minute (“Treatments”). Generally this is achieved through medication including beta blockers, calcium 
channels blockers and additional relevant medication depending on the severity of AF. 
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In addition to rate and rhythm control treatments there are also surgical and catheter procedures 
that can be used to treat AF. The maze procedure is a surgical procedure done on patients receiving open 
heart surgery for other heart ailments or who have not responded to other treatments for AF. In this 
procedure a surgeon makes precise incisions in both atria of the heart (Ad). These incisions create scar 
tissue that cannot conduct electricity.  The scar tissue disrupts the flow of abnormal electrical impulses in 
the atria that cause AF. There a variations of this procedure and changes to the technique used to create 
the scar tissue. The maze procedure has a very high success rate, but due the major surgical aspect it is 
reserved for critical patients. 
Catheter ablation is an increasingly common treatment in patients with persistent AF and no other 
heart conditions. Ablation targets cells that cause the irregular electrical signals in the atria and pulmonary 
veins. Energy is used to scar the cells causing the irregular impulses which in turn treat the AF. There are 
a variety of techniques used to target and scar the cells such as radiofrequency energy and cryotherapy. 
This is becoming an increasingly popular technique and much research is being done on ablation 
techniques and devices. As of now, very few patients require only one ablation to treat their arrhythmia. 
Throughout all of the above treatment processes prevention of blood clots is a key focus. People 
with AF are at a higher risk of blood clots due to the pooling of blood in the atria. Controlling clotting is 
especially important as the clots can travel to the brain and lead to strokes. In order to address this 
concern many AF patients take blood thinners such as Warafin, Dabigatran, and Rivaroxaban (Gutierrez 
and Blanchard). 
2-5 Cardiac Ablation  
2-2-1 Techniques 
 In the early stages of its development, catheter ablation aimed to mimic the incisions made in the 
Cox Maze surgical procedure for the treatment of Atrial Fibrillation (“Catheter Ablation Techniques”). In 
the Cox Maze procedure a series of incision and sutures are made in both atria and isolating each 
pulmonary vein to stop abnormal electrical signals (Fragakis et al.). Due to the intricacy of the Cox Maze 
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incision patterns, duplication through catheter ablations was very difficult and led to high complication 
rates.  
Research by Michel Haïssaguerre and his team of researchers found that irregular electrical 
signals responsible for AF mostly originate in or around the pulmonary veins (Jaïs et al.). The results of 
this research meant that mimicking the Cox Maze method was no longer necessary when performing 
catheter ablations. In his research he used radiofrequency energy to ablate around the openings of the 
pulmonary veins. He determined success to be the interruption of irregular or abnormally fast heart rates.  
Haïssaguerre’s research led to the development of pulmonary vein isolation (PVI) techniques.  
 With Haïssaguerre’s discovery of the general source of AF came an increase in different varieties 
of cardiac ablation and has become the foundation for AF ablation strategies. Researchers throughout the 
world began to develop varying ways of approaching PVIs (Figure 1). In addition to isolating the 
pulmonary vein, many electrophysiologists also ablate lines at varying points around the atria and other 
trigger areas to ensure that all abnormal electrical signals are addressed. 
 
Figure 1: Pulmonary Vein Isolation (Appendix A) 
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2-2-2 Energy Types 
Radiofrequency Energy 
 Radiofrequency (RF) energy is the most common type of energy used in AF ablation today. 
Radiofrequency energy is converted into heat that is used to ablate and create lesions (“Catheter Ablation 
Technology”). Use of this type of energy requires direct contact with the tissue. The depth of the lesion 
created using RF energy is dependent on the amount of energy used and the type of ablator used (Singh et 
al. 187). 
Laser Energy 
 Laser energy catheter emits light onto the cells that are targeted for ablation. The energy of the 
light causes the cells to enter into an excited state and vibrate (“Catheter Ablation Technology”). These 
vibrations create heat and lead to the formation of scar tissue. Laser energy catheters do not require direct 
contact with target cells and minimize the risk of damage to surrounding healthy cells. 
Cryothermy 
 Cryo energy exposes affected cells to frigid conditions. This exposure to cold has varying effects 
of the cells depending on the temperature they are exposed to. When exposed to temperatures between 0 
and -20°C electrical conductivity slows down and eventually stops; between -60 and -80°C scar tissue is 
formed (Singh et al. 195). 
2-5-3 Setbacks 
 Though there has been much advancement on ablation techniques and their efficacy over the past 
decade, there is still much advancement that needs to be made. Studies have found that after one ablation 
AF reoccurs in 30-50% of patients a year or more after the ablation (Lewalter et al.). After reading the 
reviews and opinions of various electrophysiologists and cardiologist, it was found that most of the 
difficulty of achieving a successful ablation in the first procedure lies in the fact that it is difficult to 
ablate in a continuous line. Though current technology helps address some of this concern, there is still 
room for significant improvement. 
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 The difficulty of the procedure and achieving a successful ablation makes it hard for new 
electrophysiologists to perform. Much of the success rates of catheter ablation is based on the skill and 
training of the electrophysiologist (Mandrola).  By making the procedure simpler to learn and execute, 
more professionals would be able to perform ablations and meet the rising demand for this treatment. 
2-3 Circumblator 
 The CircumBlator is a device that is being developed by AblaCor Medical Corporation. 
The CircumBlator will provide electrophysiologists with a one-touch ablation solution for PVI. 
This device is designed to improve the minimally invasive procedure, catheter ablation, used to 
treat atrial fibrillation. The CircumBlator aims to burn the faulty heart tissue and eliminate the 
unwanted electrical activity that causes AF. 
 Most cardiac ablations are performed inside the heart by using catheters. There are 
different ways of performing cardiac catheter ablations including point ablation, balloon ablation 
and circular array ablation. The ablation points are centered in the left atrium and create lesions. 
These lesions block the trigger points of atrial fibrillation and create a barrier to the arrhythmia. 
The goal of cardiac ablations is to electrically isolate the pulmonary vein and treat the 
arrhythmia. 
 
Figure 2: The CircumBlator (Appendix C) 
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 The CircumBlator performs these cardiac ablations in a much more efficient way. The 
CircumBlator contains a guide wire, anchor, force sensors, electrode pad and an umbrella 
ablator. In order to perform the procedure, electrophysiologists push the guide wire through a 
vein and once the wire reaches the designated area, the anchor is pulled back causing it to open 
up and secure the wire in the right area. The anchor has force and temperature sensors to ensure 
there is no unnecessary damage. Once it is fully anchored and secure, the umbrella ablator and 
electrode pad can enter. When the electrode pad and ablator is safely secure on the ablation area, 
the electrophysiologist will start the actual procedure by pressing a button to start the ablator and 
electrode pad. The electrode pad also has force sensors to make sure the energy doesn’t exceed 
the energy taken to get the anchor through the vein.  
 This procedure is more efficient that normal cardiac ablations for many reasons. The 
CircumBlator is safer and more consistent because of the anchor and electrode pad. The anchor 
provides a more stable platform which allows the umbrella ablator to be locked in against the 
tissue. In other ablators, electrophysiologists have to make sure to actively maintain contact 
between the ablator and tissue, thereby relying on physician skill to generate successful 
ablations. The electrode pad increases consistency because the energy level remains constant 
throughout the procedure. Also, all the electrodes are making contact with the tissue and adapt to 
the contours of the topography around the vein. The CircumBlator reduces the length cardiac 
ablations procedures by one to two hours. With the CircumBlator™, ablation procedures will be 
more economically attractive, because they will be shorter and more effective as a result of 
maintaining continuous ablator-tissue contact. 
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3 Methodology 
3-1 Market Data 
 The Team created a Google document that compiled all the market data that was 
considered to be prevalent to AF and ablation. The Team chose countries and regions that were 
thought to be good markets for AblaCor to implement their CircumBlator. The countries initially 
chosen to start research were Australia, Brazil, Canada, China, India, Israel, Japan, South Korea, 
Switzerland, the US, and every country in the EU. The Team researched various criteria that 
would aid in the understanding of ideal markets to distribute the CircumBlator. The Team looked 
into the population of each market to determine if there was a significant population that were or 
potentially could be living with AF. Along with looking at the population, the population of each 
region over the age of 65 was considered as most cardiac arrhythmia cases tend to occur with 
people over the age of 65. The number of arrhythmia cases that occurred within the past year was 
considered to determine the prevalence of the entire cardiac arrhythmia market. The percentage 
of arrhythmia cases that were atrial fibrillation was researched to determine the prevalence of AF 
within each region in comparison to other forms of arrhythmia. The total number of cardiologists 
and electrophysiologists in each market was a critical criterion. Data from this category was used 
to determine the number of qualified professional available in each region to perform cardiac 
ablations. It was also used to estimate the size and scope of the market for novel ablation 
devices. Not all electrophysiologists perform ablations and as a result the number of 
electrophysiologist known to be performing ablations was also taken into account. There are 
multiple types of cardiac ablations so the number of atrial fibrillation ablations per year and the 
cost of the procedure were also researched. 
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After collecting data from each of the categories, the Team created another table for atrial 
fibrillation cases for the last five years within select European countries. These countries were 
Great Britain, France, Germany, Russia and Ireland. This was used to determine if there was a 
trend in the number of individuals being affected by AF in certain areas. 
 The Team conducted our research by looking at reputable journals, national census 
websites and organizational documents about AF as well as medical databases that were about 
AF and cardiac ablation. Some of the databases and websites that we used were the Atrial 
Fibrillation Association of the US, Atrial Fibrillation Association of the United Kingdom and the 
European Society of Cardiology. The team also met Rachel Zyirek, a research and instruction 
librarian at WPI.  She guided the Team in the use of IBIS World, The American Heart 
Association and the Whitebook to assist in researching biomedical devices, marketing, medical 
procedures, and insurance. She also helped locate information on marketing a biomedical device 
and health insurance policies in international markets. 
3-2 Regulatory 
 Much of the research on the regulatory approval processes of each region was conducted 
by Matthew Hammond as shown in Appendix H. This information was gathered mostly by 
Hammond and in part by the team. The researched was centered on the procedures required in 
order for a medical device to be brought to market. This information will aid the team in the 
decision for an initial market as the quickest and most cost effective procedure will be the most 
advantageous. Additionally, some regulatory approvals are accepted in other countries and by 
obtaining an approval in a major region can open windows into others. 
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3-3 Determining Initial Markets 
 After collecting all of the research on market data and regulatory hurdles for entering 
foreign markets, the team must determine which  or regions are best suited for this product. By 
entering into too many markets, the strategy becomes too thinly spread and can suffer from a 
lack of strength in each individual market. As a team, it was decided that it would be best to 
determine three foreign markets outside of the US to enter. In order to successfully accomplish 
this task, each aspect of the information that was gathered must be analyzed for relevance to the 
devices success in the medical device market and for its significance in priority for markets to 
enter. 
3-3-1 Population and Affected Citizens 
 The population of the citizens is an indicator of the overall pool of potential consumers of 
the medical device. By looking at various aspects of the population and the prevalence of Atrial 
Fibrillation based on the proportion of sufferers to the overall population, the team can determine 
if the issue is at a large enough scale to become relevant to a wide number of physicians. 
Additionally, by looking at this prevalence, we can compare it with the number of 
electrophysiologists and cardiologists to deduce the potential for adoption in medical institutions. 
The market that is most suitable for entry would be one with a large pool of citizens and a fair to 
large proportion of those citizens either in need of the device or aware of Atrial Fibrillation. 
However, a smaller population can also be suitable based on the relevance of the condition 
amongst the citizens. 
 To best define a metric by which this can be assessed, a combination of total population, 
the amount of Arrthymia cases, the amount of those cases that are Atrial Fibrillation, and the 
prevalence of these cases per capita must flow into different pools that set apart the large 
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population ideal, the small population ideal, and the lesser desired markets. By beginning with 
the population, it can be divided simply by what would be considered a large population and 
what would be a smaller population. A simple initial division of the markets into two groups will 
keep the breakdown easy. From each group of populations, what must be determined is what 
criteria are more relevant to the larger and smaller populations. For the smaller populations, it 
would be best to see a larger percent of Atrial Fibrillation per capita as opposed to overall 
numbers. For the larger populations, the overall number of cases and the amount that are Atrial 
Fibrillation can at the very least show case the potential for marketing. 
 With the smaller population’s criteria set aside, the larger population markets are left with 
three criteria: the number of Arrthymia cases, the number of Atrial Fibrillation cases, and the 
percent of Arrthymia cases that are Atrial Fibrillation. Since the device is intended to treat Atrial 
Fibrillation specifically, the number of Arrthymia cases can be overlooked initially, with the 
exception of special cases. The first criteria would be the overall number of Atrial Fibrillation 
cases. A high number of cases show that there is prevalence in the market. If a market has a low 
number of Atrial Fibrillation cases, then there is a lack of prevalence and the population may be 
too small to adopt the device as well as desired. However, a high number of Arrthymia cases 
would show a prevalence of the overall condition and can have potential. 
 From looking at the number of Arrthymia cases, if the amount is under a set threshold, 
then there is overall too miniscule of a presence and the market is undesirable. If the market 
shows a large number of Arrthymia cases, then the percent of these cases that is Atrial 
Fibrillation can then be observed. A low ratio decreases the relevance of the device and may put 
the market into an undesirable category. But if the ratio of cases is high, then the market can find 
its place back with the larger population ideals. 
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3-3-2 Current Cardiac Ablation Climate 
 After eliminating the initial undesirable markets and splitting the rest into the large and 
small population ideals, or markets that fit into large and small scale markets respectively, the 
markets must then be further sorted by the current climate of cardiac ablation procedures. It is 
quite apparent that with a larger population, there may also be a larger number of 
electrophysiologists or cardiologists to conduct the procedure. Thus, for the larger population 
markets, the total amount of ablation procedures conducted per year must instead be observed. 
With a suitable enough number of procedures being conducted, it shows that there is prevalence 
in not just the condition, but also that method of treatment. For the markets that do not meet the 
suitable number of procedures, the number of electrophysiologist and cardiologists can be 
observed along with the number of them that are conducting ablations. If there is a substantial 
amount of electrophysiologists and/or cardiologists, then the markets can return to ideal status. If 
there is not a substantial number or insufficient data, then the number of recorded 
electrophysiologists and cardiologists conducting can be observed. This would show that even 
without sufficient data or insignificant numbers, there is at least a record of a substantial amount 
of professionals conducting the procedure. Without this record or an insignificant number in this 
regard, the market can be seen as unfit for initial release. 
 As for the small population ideal group, it has already been determined that a large 
portion of the population have Atrial Fibrillation, showing a prevalence of the condition. To 
further support this observation, the number of ablations conducted by electrophysiologists per 
year can be observed, this would show that a simpler and more cost effective procedure would 
benefit their large workloads. Should this number be too small or unfounded based on 
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insufficient data, and then the market would go under the same route as for the large population 
ideal that has an insubstantial number of ablations per year. 
3-3-3 Medical Device Market Share and Annual Investment 
 The final step for the decision flow based on the market research is to look at how the 
market share and annual investment in medical devices fair in each locale. A high number in 
either category shows dominance of the market externally or the strength of the medical device 
industry internally. This information serves to prove two advantages: a quick development of the 
presence of an ablation device in the market and the ability of the success in this market to open 
avenues into others. 
 For the large population ideals, it is expected that there would be a large amount of 
money put into investments for the medical device industry. As such, it would be best to base the 
entry decision from the percent share of the medical device market that the locale has globally. A 
high enough share shows a potential from expansion from this market, which is advantageous for 
the later stages of the marketing strategy. Countries or regions with a low share of the medical 
device market can still be seen as significant if they have an even more substantial amount in the 
annual investments in medical devices. 
 For the small population ideals, the annual investment in medical devices is the focus as a 
smaller country or region may not have as much dominance in the global market. Those with 
high numbers show a great potential for internal growth, while those with too minute of a 
number show a lack of potential for one device amongst the myriad of different ones. 
 This step in the decision flow would separate the markets into internal growth (early 
strategy) ideals and external expansion (late strategy) ideals. The desired ratio of the three 
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countries or regions outside of the US would be 2 internal growth ideals and 1 external growth 
ideal. 
3-3-4 Regulatory Measures  
 Once the markets are split into the internal growth and external expansion ideals, the 
regulatory measures that a firm must undergo to reach final approval must be analyzed. Since 
each criterion must be properly evaluated, the decision flow at this point will be based on a 
scoring system centered on how ideal these regulatory measures are. The highest scoring market 
in each category will be the end choices for initial entry. The other markets will also be evaluated 
based on any extraneous criteria that may display an importance for that country or region to be 
used. These countries or regions will then be added onto the current list of ideal markets as 
secondary options. 
4 Results and Analysis 
4-1 Market Data 
At the conclusion of collecting data for each of the regions targeted for possible entry, 
there were many gaps in specific region information. The majority of these gaps were regarding 
the number of qualified persons performing ablations and the volume these professional were 
performing. Despite the lack of information, the original list of countries and regions was then 
organized into markets for initial entry, markets for expansion, and those where further 
information and market monitoring was needed. In order to overcome the lack of data for certain  
and regions this ranking was primarily based on population size, reported number of AF cases, 
the number of AF ablations performed each year, and the number of electrophysiologist or 
cardiologist who have the ability to perform the procedure without additional education.  
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 Based on the criteria we found that the US and the EU would be the most ideal areas for 
entry and thus should be pursued first. Each of these regions has seen a significant increase in 
their elderly populations, and as life expectancies continue to increase the prevalence of AF is 
also anticipated to increase. In addition to the prevalence of elderly, both regions also are 
reported to perform the most AF ablations per year, with 43,118 in the EU and 10,000 in the US 
To perform these ablations there are a minimum of 2,388 active cardiology professionals 
performing ablations in the two regions. From the population data alone we found the US and the 
EU to be the best regions for initial entry; however, medical device spending in both areas 
accounts for more than 74% of the total market. Based on this information these two regions are 
not only ideal for immediate entry, but they also have the potential for continued and sustained 
growth.  
Japan, Canada, South Korea, Australia, Brazil, and India were found to be countries that 
could be considered for expansion.  Most of these countries, such as Japan and Canada, were 
also found to have rapidly increasing elderly populations. The aging population makes these 
markets suitable for entry; however, the lack of information available in regards to the number 
professionals who are or have the ability to perform ablations detracts from the attractiveness of 
these markets. The lack of information on the number of AF ablations being performed makes it 
difficult to determine the size and potential growth of the market. Without information in regards 
to the number of electrophysiologists we felt that we could not accurately determine the ease of 
implementation amongst professionals in these countries as well. Though the number of AF 
cases can indicate the disease’s presence in the populations, factors such as medical tourism need 
to be taken into considerations. For markets in this tier, further explorations of the regulatory 
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processes were taken into consideration to determine the overall attractiveness of the county’s 
market. 
Finally Russia, China, and Israel were all found to be countries that were not suitable for 
immediate entry or entry in the near future. For all three of these nations there was not 
substantial or reliable enough information to provide a recommendation for entry. More 
extensive information regarding the size and scope of the AF market is necessary before these 
nations can even be considered for potential entry. 
4-2 Regulatory 
 At the conclusion of the collection of basic market data three main markets emerged that 
would be most ideal based on population; the US, EU, and Japan. The regulatory processes for 
these and all additional regions clarified some of the top market picks while eliminating others. 
4-2-1 Regulatory Processes by Market 
 The US regulatory process for medical devices is conducted by the FDA and is similar to 
other regulatory processes. However, despite approval in foreign markets the FDA requires 
clinical trials to be done within the US. These trials must include between 500 and 1,000 patients 
and is expected to cost $5-10 million. The unique aspect of the US regulatory process in addition 
to the local clinical trials that must be done causes the approval process to take between five and 
ten years on average. 
 The EU requires medical devices receive a CE Mark before they can distributed 
throughout the member countries. Despite being accepted throughout the EU, certain member 
countries have stricter interpretations of the CE guidelines. Like the FDA, CE guidelines also 
require clinical trials that are done within the EU. Based on the approval of similar catheter 
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ablation devices within the last ten years it can be deduced that the Circumblator will need 
between 200 and 300 patients for their trial. Once a CE Certificate has been received the firm can 
begin registering the device for distribution in specific EU countries. The CE certificate is valid 
for one year and requires auditing every year thereafter. In order to comply with the yearly audits 
it is essential that post-market surveillance is conducted. This regulatory process generally costs 
$2-3 million. 
 The Japanese regulatory process for medical devices, while in compliance with ISO 
13485, is unique from the FDA and CE approval processes. Unlike the previous two markets, 
medical device classification is not based on the type of device, but rather the risk associated 
with it. Similarly to the US, Japan requires local clinical trials; however the number of patients 
required varies depending on the level of risk associated with the device. For high risk devices 
between 400 and 600 participants are required. A benefit to getting approval in Japan is that the 
approval certificates do not expire; however the process of approval is long and cost associated 
with completing clinical trials within Japan are high. 
 Outside of these three markets the process for regulatory approval in generally faster and 
more cost effective. Many of the countries targeted for international market entry follow a 
similar approval style to that of the CE Mark. This being the case many of these countries will 
accept clinical trial data from foreign countries, thus shortening the time and cost to approval. 
Many of the countries that do not currently have regulatory processes similar to those of the US, 
EU, and Japan are currently in the process of reformatting and refining them do be similar. 
4-2-2 Market Analysis 
 Taking into consideration both the market data and the regulatory requirements of each 
market considered, it was found that basing countries and regions targeted for entry solely on the 
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potential for AF cases was not an effective strategy. This plan did not guarantee device 
implementation. As opposed to the previous methods for target market determination, annual 
medical device spending provides a better insight into the potential for product implementation 
within the region. 
 Taking this newly defined path into consideration, it was found that the original three 
markets for consideration were also those with the highest annual medical device spending, 
making up more than 75% of total medical device spending. Medical device spending not only 
gives a clear insight into the benefits of entering a specific country or region, it also allows for 
better comparison between markets. For example when looking at markets with similar 
population compilations and number of ablating professionals, the market with the higher 
medical device spending is likely to provide a better, more receptive market for entry.  
Considering this method of determination, large emerging markets such as Brazil, Russia, 
India and China, fall behind countries with higher expenditures despite less stringent regulatory 
processes and larger AF affected populations. Conversely, smaller markets can receive higher 
consideration despite the number of people affected by AF. Countries with regulatory processes 
similar to those of the CE Mark would fall into this category for further consideration. 
4-4 Determining Initial Markets 
 The development of a successful decision flow diagram required an understanding of the 
data that we had collected and how each category showcases a market’s suitability for the device 
and its potential acceptance. Each threshold would not only filter out countries into those that are 
desirable and those that may not be the best at the moment. Additionally, the decision flow 
diagram will designate each market into a strategic category. One of the categories is the Internal 
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Growth Ideals may be an apt idea. These markets spend quite a bit on investments for biomedical 
devices and thus can hasten the presence of the device and its success within the market. The 
other category is the External Growth Ideals. While these countries or regions may also have a 
prospect of internal growth, their dominance in the global market of biomedical devices is strong 
enough to allow for expansion on a global scale. The Internal Growth Ideals are an early strategy 
option, setting the foundation and example of the device’s success and can be used to gauge how 
successful the device will be on a global scale. The External Growth Ideals are more of a later 
strategy option, not to say that entry into these markets should be delayed by any means, but that 
the success in these markets could mean a boost to expansion later on.  
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4-4-1 The Decision Flow Diagram 
 
Figure 3: The Initial Market Decision Flow Chart (Appendix F) 
 The decision flow diagram above illustrates the flow of the decisions made based on the 
criteria and the values observed for each criterion. 
 The flow diagram begins by looking at the populations of each country or region 
observed. It was decided that 250 million would be the cutoff point to sort the markets into initial 
large and small categories. This number was generated from the average population of each 
country and region with the deletion of the two outliers, China and Australia. From the 
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separation into these sub groups, the rest of the data was observed considering what qualities an 
ideal market with a large and small population would have. For the smaller populated countries, 
the focus relied on the prevalence of Atrial Fibrillation by looking at the number of cases per 
capita. With at least 0.5% of the population with Atrial Fibrillation, the market has a large 
enough portion suffering from it that there is a need for treatments that successfully remedy the 
condition. If the condition is prevalent, the focus then moves on to a potentially high patient 
count for professionals that conduct treatments. The markets that have professionals with high 
counts of treatments per year may have the need for a quicker and more cost effective procedure 
allowed by the use of the CircumBlator™. For the larger markets, the aim is to find the ones with 
a higher general prevalence of Atrial Fibrillation. If there is not a high enough prevalence of the 
condition, a high number of Arrhythmia cases with a majority of those cases being Atrial 
Fibrillation can still show a need for treatment options. And if the country or region is already 
conducting many treatments, the potential for adoption of a more efficient procedure is 
significant enough to investigate further. 
 If there is not enough evidence to show a need of the device based on either the amount 
of ablations conducted or the number conducted by each professional, then the amount of 
professionals must be evaluated. The prevalence of the treatment may not be high, but there still 
may be a multitude of clinics and professionals conducted other treatments. If these values show 
a sizeable market of buyers of the CircumBlator™, then the decision relies on either the annual 
investment for medical devices in the smaller countries or the global market share of the larger 
ones. Those seen with a high annual investment in medical devices are internal growth ideals, 
meaning that the internal funding of the industry can lead to further developments of the device’s 
success in the market. The countries or regions with the highest global market share are the 
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external growth ideals, meaning that from the success within these countries or regions can 
expand into other markets. 
4-4-2 Regulatory Scoring  
 After reviewing the results of the regulatory research, it was determined that instead of a 
scoring system, it would be more strategic to start in a country or region where regulatory 
approval can spread to others. The country and region that have this advantage are the US and 
the EU. Approval from the US Federal and Drug Administration can extend approval to other 
countries such as Brazil. Additionally, the CE mark in the EU is widely accepted around the 
world. With the potential to find success and being required to pass only two approval processes 
to expand, the US and the EU are ideal choices. 
4-4-3 The Initial Market Choices 
 The top scoring markets found through the decision flow chart are the US, the EU, and 
Japan. Other countries that have made it through the decision chart as the internal growth ideals 
are Canada, Brazil, and Australia. Another country that also fit the external growth ideals was 
China. However, with the advantages brought upon by FDA approval and CE marking 
acceptance, the US and the EU were deemed to be the best initial markets to enter. Additionally, 
for the EU, Germany was also ranked as an internal growth ideal and would be a suitable starting 
point for entering the EU. 
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5 Conclusions and Recommendations 
5-1 Markets for Entry 
 Given the both the market data and regulatory processes, it is clear that the two primary 
markets to be considered to begin approval and distribution of the Circumblator are the US and 
EU, more specifically Germany. These markets comprise the majority of annual investments in 
medical devices and can support additional international growth in the future. However, we 
recommend that to begin device approval should be sought in Germany.  
 We recommend Germany as a beginning market because not only is it a large investor in 
medical devices, but also the regulatory procedures are swifter and less expensive than pursuing 
similar action within the US. The CE Mark being the standard for many other medical device 
regulatory processes around the world means that distribution of the device into those markets 
would be relatively simple once the original CE Certification had been received. By receiving a 
CE Mark, the CircumBlator would have the ability to enter into other large market with high 
numbers of arrhythmia, aging populations, and high investments in medical devices  
By pursuing Germany as the primary distribution market as opposed to the US, AblaCor 
can save at least $5,000,000 in regulatory fees and 2 years. With the time and money saved 
AblaCor can distribute the Circumblator throughout the EU and use the profits from this 
distribution to fund US based clinical trials.  
5-1-2 The German Market 
 Germany is Europe’s largest market for medical devices and the world’s third largest, behind the 
US and Japan. Although in decline, Germany’s population of Germany still accounts for around 20% of 
the population. Germany counts 2,000 hospitals; 2,000 medical supply stores; 1,200 rehabilitation 
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centers; 21,500 pharmacies; and 150,000 doctors’ offices. Government funding of hospital projects has 
remained static; major areas of opportunity are seen for private hospitals and clinics, which have a 20% 
market share. Demand will mainly be driven by demographics and a substantial increase in the number of 
patients and by the need for more efficient procedures. The German medical market expects a sales 
growth of approximately 6% this year, with continued upwards trends predicted for next year as well. The 
medical technology sector continues to be strong on innovation and growth and will provide excellent 
potential for US suppliers of innovative and price-competitive products. US medical device exporters to 
Germany continue to hold a 27-30% import market share, depending on product. 
The “Medical Technology Action Plan” pools the Federal Ministry of Education and Research’s 
varied funding activities and programs under three main topics: Medical technology in rehabilitation and 
care (intelligent implants); Molecular imaging; Medical technology for regenerative medicine. Incentives 
are provided as R&D project grants/cash incentives with a maximum 50% of eligible project costs. The 
EU is subsidizing transnational R&D through its 7th Research Framework Program. A budget of 6.1 
billion Euros for the period 2007 to 2013 has been earmarked for health research. 
For US companies, the German market which is the largest in the EU continues to be 
attractive in numerous sectors and remains an important element of any comprehensive export 
strategy to Europe. While US investors must reckon with a relatively higher cost of doing 
business in Germany, they can count on high levels of productivity, a highly skilled labor force, 
quality engineering, a first-class infrastructure, and a location in the heart of Europe.  
The most successful market entrants are those that offer innovative products featuring high 
quality and modern styling. Germans are responsive to the innovation and high technology evident in US 
products, such as computers, computer software, electronic components, health care and medical devices, 
synthetic materials, and automotive technology. Germany boasts one of the highest Internet access rates 
in the EU and new products in the multi-media, high-tech and service areas offer great potential as 
increasing numbers of Germans join the Internet generation. Certain agricultural products also represent 
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good export prospects for US producers. Price is not necessarily the determining factor for the German 
buyer, given the German market’s demand for quality. The German market is decentralized and diverse, 
with interests and tastes differing dramatically from one German state to another. Successful market 
strategies take into account regional differences as part of a strong national market presence. Experienced 
representation is a major asset to any market strategy, given that the primary competitors for most 
American products are domestic firms with established presences. US firms can overcome such stiff 
competition by offering high-quality products, services at competitive prices, and locally based after-sales 
support. For investors, Germany’s relatively high marginal tax rates and complicated tax laws may 
constitute an obstacle, although deductions, allowances and write-offs help to move effective tax rates to 
internationally competitive levels. 
5-1-2 German Reimbursement 
 
Before applying for German reimbursement, make sure that the medical device is CE- certified. 
Once certified, the medical device is eligible to apply for reimbursement in Germany. All applications for 
medical devices are submitted to the umbrella organizations of the Statutory Health Insurance (SHI). You 
must provide information about the device such as suitability, safety, quality, requirement and medical 
benefits.  
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Figure 4: German Reimbursement Process (Appendix G) 
Germany’s hospital funding is regulated by the Hospital Financing Act. The Act makes each state 
responsible for covering large investment costs and the procurement of assets with a long economic life 
typically three or more years. These types of investments need to be negotiated and agreed between the 
state and the hospital in question. Inpatient hospital activity is the responsibility of each patient’s SHI or 
private insurer. Only the top 3% of people in Germany have private insurance. The principal mechanism 
of inpatient activity reimbursement to hospitals by the SHIs or private insurers is called the German DRG 
or G-DRG. 
German Diagnostic Related Groups (G-DRG) is the German modification of the World Health 
Organization’s ICD-10 classification system. Every year the Deutsche Institut für Medizinische 
Dokumentation und Information (German Institute for Medical Documentation and Information) or 
DIMDI reviews the annual ICD-10 released by the World Health Organization and modifies the G-DRG 
in order to be somewhat similar to the ICD-10 but also works for the German health care system. 
 While the DIMDI has the responsibilities of maintaining the G-DRG’s diagnostic and procedural 
codes, the Institut für das Entgeltsystem im Krankenhaus Siegburg (Institute for the Hospital 
Remuneration System) also known as the InEK is responsible for the collection and processing of hospital 
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costing data, the updating of the funding units associated with each funding code and the updating of the 
funding codes themselves. They are also responsible for certifying the logic system available to German 
hospitals. The Statutory Health Insurance or private insurer will then pay the hospital for the procedure 
based on where the procedure falls within the G-DRG code. 
The reimbursement of newly introduced technologies depends on the availability of specific 
diagnostic and procedure codes, as well as the adequate uptake and correct coding of the new technology 
by the hospitals that participate in InEK’s calculation system. InEK is updating G-DRG on an annual 
basis. Because of this, it may take longer to successfully fund a new technology or create new funding 
codes for it.  
Recognizing the need for a mechanism allowing innovation within the G-DRG system, the InEK 
has created an “on-top” funding process for innovative products. This process, known as NUB (Neue 
Untersuchungs- und Behandlungsmethoden) Application can be filed by hospitals only for technologies 
that have just been introduced in Germany. Every hospital will need to apply separately (electronic 
application at InEK) and the “on-top” payment (if the application is approved) will be available only to 
the hospitals that applied for it and not to every hospital in Germany. Approved applications are 
subsequently monitored by InEK and should the new technology be adequately used; correctly coded; 
and, exhibit a cost profile of sufficient difference, the InEK may integrate it permanently to the G-DRG. It 
should be noted that InEK makes no decision on the actual amount of the “on-top” payment. That will 
need to be directly negotiated between the successful hospital applicants and the SHIs. The NUB pathway 
has the potential to accelerate market access for new technologies but requires significant effort from its 
users.  
5-2 Next Steps 
 For future teams looking to expand the scope of the target market for the 
CircumBlator™, this is a general guideline for approaching that task. Each step in the guideline 
provides a basic objective that should be reached in order to make a fully educated decision as to 
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where to enter and how to enter that market. Future teams may take these guidelines and add 
more to it if they wish to make a more definitive decision. 
5-2-1 Narrow List 
 When generating a list of countries and regions to research, the future team should first 
narrow a primary list down to about three. By utilizing a metric, such as the annual investment in 
medical devices, the team can find the strongest markets to conduct extensive research on. The 
number of narrowed down countries and region can be changed dependent on the budgeted time 
to research. The metric of annual investment in medical devices is useful in narrowing down 
markets due to the overall financial acceptance of medical devices within. Those with the highest 
annual investments supply a financial foundation in the industry that can increase the ease at 
which the device finds success. Of course, any other evidence that may highlight a market as one 
with a high need, either through political changes or changes in the market, can include that 
country or region to the list. Regulatory means can also be a way of narrowing the markets. If a 
CE mark has already been obtained, then looking into countries that accept it will help, 
especially if there is no additional approval process beyond having the CE mark. 
5-2-2 Gather Data 
 Once the team has determined the markets that it will research, the team should look into 
these values with these thoughts in mind: 
Number of Atrial Fibrillation Cases 
 This value shows the basic population of the target users and possibly consumers of the 
device. Attempt to look into the concentration of cases and other factors of the prevalence of 
Atrial Fibrillation beyond the number of cases. Are there regions in the market that are 
experiencing predominantly more cases than the rest? Is there a correlation between the aspects 
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of the market or regions in the market and the number of cases? By answering questions such as 
these with your research, the team can make more sense of the value and paint a picture of the 
environment surrounding Atrial Fibrillation in the country or region. 
Number of Electrophysiologists, Cardiologists, and Clinics 
 The purpose of researching these quantities is primarily to gauge the size of the target 
market. Are these professionals or clinics providing treatment for Atrial Fibrillation? Are they 
conducting cardiac ablations? By focusing the research into a detailed account of the history of 
treatment of Atrial Fibrillation in the market, the team can understand the target market’s current 
state and the potential impact the introduction of the device will have in the country or region. 
Additionally, this research will aid the team in finding the first customers of the device. 
Number of Ablations per Year 
 The team can use this research to focus their entry efforts and gauge the competition 
within the market. Focus the research on more than just the total number and look into which 
clinics have the most traffic and if there are any growing frustrations with how ablations are 
currently being operated. Since this research should uncover other companies that market cardiac 
ablation devices in the country or region, this is also an opportune time to research those 
companies as they will become direct competitors. 
Reimbursement Process 
 Countries or regions often have differing medical reimbursement systems, especially 
when comparing a majorly private healthcare system and a social one. For example, the 
reimbursement process in the US will vary widely based on the policies of the individual health 
insurance companies. By understanding the processes in the markets the team is researching, the 
sponsoring company can better understand the flow of money and how they will earn revenue. 
34 
 
Percent Share of the Medical Device Market 
 This value will aid in ranking the markets based on the strategic potential they have in 
expanding to other markets. A market that has a major share of the medical device market is one 
that has the leverage needed to expand. Another possibility is that having such a large share 
means that other countries respect success in that one, leading to greater success and acceptance 
when expanding to those countries. 
5-2-3 Prioritize the List 
 After gathering all of the necessary data, the team can use, transform and use, or generate 
a new decision flow and prioritize the markets from the most ideal to the least. 
5-2-4 Research Regulatory Processes 
 Starting from the highest priority market, research the regulatory process required to 
obtain approval in the country or region. This information can often be obtained in full by the  or 
region’s department or ministry of health. The key points to focus on are the average times to 
approval, the trial size required for clinical testing, and the average cost to approval. This 
information is critical, especially if you still require a form of internationally accepted approval, 
such as FDA approval or a CE Mark. 
5-2-5 Compare Regulatory Process to Resources  
After gathering the regulatory data and conducting a cost analysis, the team should 
compare the results between the markets listed. If any of the markets fall out of the range that the 
sponsoring company can handle, then move the market down the list. After comparing and 
moving the countries and regions around, the team should have one or two definitive ideal 
countries or regions. These markets are ones that show a potential for an accepting market and a 
regulatory process that will not bring the company into failure. 
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5-2-6 Final Market  
 Once the final market has been decided for entry, begin the process toward approval. If 
an international approval is accepted and has already been obtained, you may be able to almost 
directly enter the market. 
5-3 Conclusion 
 What the team found that were the most important points in the process of deciding an 
initial market are the market data, the regulatory process, and the reimbursement process. By 
combining these three factors, the atmosphere around medical device markets can be properly 
assessed. The decision to enter Germany involved adequate analysis, but by following the 
guidelines with proper focus will allow for future teams to make a decision after finding 
exhaustive information. 
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7 Appendices 
Glossary of Terms 
Competent authority – Any governmental regulatory agency responsible for the registration of 
medical products within that country. Most often refers to device registration in European 
countries after obtaining a CE Mark. 
DIMDI- German Institute for Medical Documentation and Information 
EFTA – The European Free Trade Association is the area in which CE Mark directives apply. 
Includes the EU and neighboring Norway, Switzerland, Lichtenstein, and Iceland. 
External Market Growth – Largely populated market with high global market share. This 
market has potential for expansion and often also has high annual investments in medical devices 
and internationally accepted regulatory approvals. Ideal for a later strategy or overall focus. 
G-DRG - German Diagnostic Related Group, it is the German modification of the World Health 
Organization’s ICD-10 classification system. 
GHTF – The Global Harmonization Taskforce is a voluntary organization of medical 
professionals that promote am international unified approach to medical product registrations. 
InEK - Institute for the Hospital Remuneration System 
Internal Growth Ideal – Market with high annual investments in medical devices. Shows 
potential for quick growth within the market. Ideal for early strategy. 
ISO – International organization for Standardization, international guidelines for nation’s 
regulatory processes. ISO 13485 and 14155 are the most commonly adhered to guidelines. 
ISO 13485:2003 Certification - A widely accepted certificate demonstrating compliance with 
the quality management systems outlined in ISO13485. Accepted in nearly every nation. 
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Large Scale Market – A largely populated market. High potential for large annual investments 
in medical devices and global market share. 
Notified body – Third party authorized to issue a CE Mark by the EU. May also be qualified to 
carry out other certifications (such as Brazilian INMETRO certification). 
QMS - The organizational structure, procedures, processes and resources needed to ensure 
consistent performance in manufacturing. Proof of sufficient quality management systems is 
required in all regulatory process and is usually fulfilled by ISO standards. 
Regulatory Liaison – A person or company responsible for handling regulatory and sometimes 
distribution of a device in a country you are not based in. Requirements, importance, and legal 
capabilities for a liaison vary greatly by country. 
SHI - Statutory Health Insurance 
Small Scale Market – Smaller population markets. May have high annual investments in 
medical devices or concentrated prevalence of cases. 
STED Documentation – Suggested standardized technical file documentation promoted by the 
GHTF. Not universally adopted but frequently accepted in place of technical documentation. 
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Appendix A: Pulmonary Vein Isolation 
 
Source:  Techniques and Technologies for Atrial Fibrillation Catheter Ablation  
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Appendix B: AblaCor™ 
AblaCor Medical Corporation (formally Automated Medical Instruments) is a company 
based in Needham, Massachusetts and was by founded by WPI alum, Martin Sklar. AblaCor 
Medical Corporation is an early stage medical device company that is dedicated to the 
development of revolutionary, minimally invasive products that will transform catheter ablation 
into a first-line treatment for patients with atrial fibrillation. AblaCor is designing a device called 
the CircumBlator which is a one-touch ablation solution for pulmonary vein isolation. It is also 
designed to improve the catheter ablation procedure. AblaCor recently was a finalist in the 
MassChallenge which is a competition designed to help early-stage entrepreneurs with the 
resources they need to launch and succeed as soon as possible. 
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Appendix C: CircumBlator 
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Appendix D: Market Data 
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Appendix E: Regulatory Information 
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Appendix F: Decision Flow Chart 
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Appendix G: German Reimbursement Flow Chart 
47 
 
Appendix H: Regulatory Analysis Report 
 
 MQP – FRH – FHO2 
 
  
Regulatory Feasibility Analysis for a New Atrial 
Fibrillation Ablator in Selected Countries 
A Major Qualifying Project Report 
Submitted to the Faculty of the 
Worcester Polytechnic Institute 
in partial fulfillment of the requirements for the 
Degree of Bachelor of Science in 
Management by 
______________________ 
Matthew Hammond 
Approved:  
_______________________   _______________________  
Martin Sklar, President and CEO  Frank Hoy, Ph.D  
Automated Medical Instruments   Paul R. Beeswick Professor of  
Project Sponsor      Innovation and Entrepreneurship  
Project Advisor  
_______________________  
Jerome Schaufeld, Ph.D  
Professor of Practice  
Project Co-Advisor  
48 
 
Abstract  
Medical device registration for class three devices, such as a catheter ablator, can be a long 
and difficult process. The regulatory requirements can vary greatly by country, overlap and benefit 
one another, or require repeating a certification depending on the country in question. Determining 
the order in which regulatory approval is pursued affects the size of the market in which a new 
device may enter. Prior approval on major facets such as clinical trials may greatly reduce the costs 
of entering a particular country if the data from an outside source is deemed acceptable. This creates 
a complex problem where start-ups who cannot afford to pursue regulatory approval in all major 
markets simultaneously must carefully chose and enter individual markets a few at a time. This paper 
compares ten nations and regions against one another and outlines a suggested order of entry.  
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Background  
Atrial Fibrillation is the most common form of arrhythmia, accounting for approximately 40% of all 
cases of arrhythmia. Currently, there exist only two options for arrhythmia patients, surgical ablation 
or going on anticoagulants, such as warfarin, for the remainder of one’s life. The surgical ablation 
process is currently done by catheter point ablators, a technique that was introduced in the late 
eighties, and has changed little since then. Current catheter ablation operations have a wildly varying 
success rate, between 50-80%, and are highly dependent on the skill of the electrophysiologist 
performing them.  
Automated Medical Instrument’s Circumblator claims to fix this problem by removing significant 
chance of surgeon error from the procedure. The Circumblator anchors itself within the pulmonary 
vein using a stent-like device. The ablation is then performed using a circular radiofrequency ablator 
around the vein. This process improves upon existing methods by using the anchor to hold the device 
in place, freeing the surgeon of the task of ablating several individual points by hand. The results 
should be a major increase in the success rate of catheter ablation.  
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Project Purpose  
Understanding the regulatory process of a country is a critical component in determining the cost and 
benefit of entering a particular nation. Regulatory systems are complex; often impact one another, 
and approval runs the risk of becoming increasingly costly if the applicant is not prepared. The 
approval process in all countries must be able to show safety and efficacy of the device making the 
quality of clinical data the key factor. Most nations accept clinical data from studies conducted 
outside their boarders but will independently determine whether or not the data is considered 
sufficient for “statistically significant results” as defined by ISO 14155. As a result, it is important to 
conduct initial clinical trials in an area with high standards and a high reputation for quality. The 
three regulatory systems with the highest reputations and most widely accepted sources of clinical 
data are in the US, EU, and Japan.  
Once the first location of clinical trials has been chosen, other regulatory processes may be 
considered as though they had sufficient clinical data (if outside data is accepted). Whether or not 
clinical data from the first trial location are accepted elsewhere will greatly impact the order of entry 
internationally.  
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Methods  
European CE Marking Process  
The European approval process is a decentralized and highly efficient regulatory approval route 
designed to give all member countries access to new medical technologies. CE Marking is not a mark 
of quality, the process of CE Marking is actually a “self-declaration” whereby the manufacturer 
claims to be in compliance with the guidelines necessary for free trade within the European 
Economic Area (EEA). The CE Mark effectively functions as a “pre-market approval”, which 
includes the lengthy technical documentation and collection of clinical data processes. This is the 
most expensive aspect of the approval process and registering a device in individual European 
nations with a CE Mark is quick and inexpensive or, in many cases for class III devices, not required 
at all.  
A class III device must prepare and submit two documents to a notified body in order to receive a CE 
Mark. The first is proof of implementation of a Quality Management System (QMS) that complies 
with ISO 13485 guidelines. This is the first required step in all regulatory approval processes and in 
all but two of the observed countries (USA, Brazil) is based on ISO 13485 requirements. The second 
document is a Design Dossier, an extensive technical file that will require a large amount of clinical 
data. Clinical trials for a CE Mark are best conducted in European countries with the strictest 
interpretations of the CE guidelines such as the UK, Germany, France, Sweden, or Switzerland or in 
partner states that have made large efforts to comply with CE guidelines such as Canada and 
Australia. Clinical trials require approval from a Competent Authority (CA) from the countries they 
are to be conducted in. Competent Authorities are the regulatory bodies of the individual nations 
within the EFTA and have based their regulatory processes around CE guidelines. The size of 
clinical trials must demonstrate proof of safety in man and proof of parity to existing devices at a 
“statistically significant level” (ISO 14155). What constitutes “statistically significant levels” of data 
is based on precedence and the expected level of risk of the device. For example, a new catheter 
point ablator awarded a CE Mark in 2006 conducted a 210 patient clinical trial (sharps.org) where the 
more novel, less understood Cryoballoon catheter ablator required a 240 patient pivotal trial 
(Medtronic.com).  
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Based on this and other invasive electrophysiological devices approved in the last ten years we can 
expect a clinical trial size for the Circumblator to range between 200 and 300 patients.  
With this information in hand, an authorized representative called an EC-Rep located within the EU 
must be appointed and submit the applications to a notified body. If the audit is successful and the 
device is approved the notified body will then issue a CE Certificate. This certificate is valid for one 
year after which continued approval is subject to yearly audits by a notified body. Upon being issued 
a CE Certificate, the manufacturer may produce a Declaration of Conformity and begin registering 
the device in the countries which require registration and begin distribution. Registration is 
frequently not required for class III devices as many nations rely on the yearly notified body audits to 
ensure quality. However, even if registration is not required, distribution must still comply with all 
CE directives which include translating all labeling into the local language. Post-market surveillance 
must also be conducted to ensure successful yearly audits.  
Regulatory Approval Process in the US  
Regulatory approval in the US is conducted by the FDA. The FDA approval process is separate from 
all other regulatory processes meaning US-based clinical trials will always be required regardless of 
the status of foreign approval. Unique standards must adhered to similar to ISO protocols, with 
random inspections in place of yearly reviews. The only international standards followed during the 
FDA regulatory process are the STED document formats. Despite these drawbacks, the US remains 
one of the most sought after markets due to its status as the single largest buyer of medical devices. 
The international reputation and acceptance of FDA approval is second only to Europe.  
The first step in seeking regulatory approval from the FDA is implementing a Quality Management 
System. The FDA’s QMS predates ISO standards and does not recognize ISO 13485 approval. 
Instead, the implemented QMS must follow the 21 CFR Part 820 requirements, also known as the 
current Goods Manufacturing Process (fda.gov). As the CircumBlator is a substantially novel device, 
a Pre-IDE trial will likely be required as the device is not substantially equivalent to existing market 
products. This trial is small in scope, with the goal of demonstrating safety in man and parity to 
existing devices. Once IDE approval is granted, pivotal trials may start. A pivotal trial conducted in 
the US will require 500 to a 1,000  
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patients at an expected cost of $5,000,000 to $10,000,000 (gmplabelling.com). Once pivotal trial data 
is collected, a completed PMA application may be submitted. The PMA review will theoretically 
take no longer than 180 days and is contingent on site inspections.  
The FDA’s regulatory process is regarded as one of the highest standards in the world. Part of this is 
the scope of pivotal trials in the US; the FDA reserves the right to reject devices due to new 
technologies not being “substantial improvements” over existing ones. Despite this, the FDA is 
plagued by bureaucratic issues that impact the approval process, including outdated infrastructure 
and a high turnover rate. Delays are common meaning the approval process within the US can vary 
between two to five years.  
Regulatory Approval Process in Japan  
Much like the FDA, the Japanese approval process is known internationally for its high standards. 
Also, like the FDA, Japanese approval is a long and difficult process that requires clinical trials 
conducted within the country’s boarders regardless of international recognition. Japan is the fourth 
largest individual buyer a medical devices, behind the US, Germany, and France.  
Regulatory approval in Japan begins with the appointment of a Marketing Authorization Holder, 
called a D-MAH, which will act as a regulatory liaison in the country. Device classification must be 
determined as Japan has a 4 tier classification system where tiers 3 and 4 do not clearly specify the 
kinds of devices in each category. Instead, device classification is done by an arbitrary approximation 
of risk of the device. Once this information is known, the D-MAH may submit a form for Foreign 
Manufacturer Accreditation to the PMDA. A quality management system must be implemented that 
complies with ISO 13485 as well as the Ministry of Health, Labor, and Welfare Ordinance #169. At 
this stage, clinical trials must be conducted in Japan. Clinical trials in Japan are costly, for high risk 
devices 400 to 600 Japanese patients may be needed. Combined with the costs of maintaining 
Japanese contacts, the costs of running clinical trials in Japan is comparable to clinical trials in the 
US. Once clinical data is collected a pre-market approval form may be submitted as well as technical 
files which follow the STED format. Pre-market Approval certificates issued by the PMDA do not 
expire.  
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Approval in Japan is unfortunately not a quick or easy option for a small company in the US. Japan 
places high importance on the status of home-country approval although it is not required. 
Additionally, the role of the D-MAH is much greater than most regulatory liaisons, they possess 
certain right in the country related to devices they help approve. Choosing a D-MAH that is part of 
an international medical device distributor or consulting firm is recommended.  
Cost of Regulatory Approval between the US, EU, and Japan  
Due to the huge costs associated with clinical trials, the optimal path for approval and access to all 
major markets is best done sequentially rather than concurrently. Outside approval only officially 
benefits the regulatory process in Europe, unfortunately the CE Mark is also the quickest and least 
expensive way to obtain one of the three major approvals. Furthermore, Japan places a high value on 
the status of home-country approval. The order in which approval is sought after in these three 
markets greatly affects access to the worldwide medical device market. Obtaining approval in one of 
these three bodies would normally indicate that you have sufficient clinical data to pursue regulatory 
approval in almost any other nation in the world without the need for additional clinical trials.  
Due to Japan’s foreign device constraints, smaller market, and comparable regulatory costs, it only 
makes sense to seek Japanese approval following US approval. This makes the question of first 
major market a decision between the EU and the US. Approval in the EU comes at an expected cost 
of $2-3 million and grants access to 30.3% of the medical device market. Approval in the US comes 
at an expected cost of $5-10 million, grants access to 44.4% of the medical device taking roughly 
twice as long to gain approval. With the metric of “cost to access 1% of the market” it becomes clear 
that Europe is a much more cost effective first market (US: $112,000-224,000 per 1%, EU: $66,000-
100,000 per 1%). Combined with other factors, such as the acceptance of the CE Mark 
internationally, aging population of most European nations, and lower total capital needed to get to 
market, Europe becomes the best choice. Once European approval is granted in the form of a CE 
Mark, access to all other international markets becomes substantially easier, especially in many 
wealthy smaller nations that make up the list of top medical device buyers (Canada, Australia, and 
South Korea). Consecutively pursuing approval in 
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the US and then Japan is also recommended, as they represent a combined 54% of medical device 
purchases worldwide.  
Regulatory Approval outside of the Top Three Markets  
With clinical data from European trials, the regulatory timetable and cost to access markets in 
multiple other nations drops significantly. These countries regularly accept clinical data from outside 
their boarders and will likely not require additional studies if the product possesses a CE Mark. 
However, although many nations have streamlined their regulatory processes to better match the 
European model, the regulatory agencies still maintain the final say on approval within a specific 
nation. This section covers the regulatory processes for select countries based on their market size.  
Australia  
The Therapeutic Goods Administration (TGA) is the regulatory body in charge of medical device 
approvals in Australia. The TGA, in an effort to combat medical tourism and other failings within its 
old approval system, redesigned its classification system and regulatory process along the guidelines 
of the Global Harmonization Task Force (GHTF). Depending on the scope and requirements of 
clinical trials, it may be worthwhile to pursue Australian and EU approval concurrently, as the TGA 
is a Notified Body capable of issuing a CE Mark.  
Similar to Europe in its initial steps, the registration process for Australia requires proof of 
compliance with ISO 13485. When submitting a Design Dossier, the European standard equivalent 
may be used. The Australian regulatory process differs from the European system during the 
submission process. Medical Device registration in Australia requires a regulatory liaison that resides 
in the country. Through this liaison, manufacturers evidence (CE Mark) is submitted and the device 
is entered into an electronic registry called the DEAL system. If approved, the approval will be 
posted on the TGA website and a certificate will be issued with the device’s registry number. A small 
fee is required to submit the manufacturer’s evidence and list the device online.  
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Brazil  
Device registration in Brazil begins with the appointment of a Brazilian Registration Holder. This 
must be a company with locations inside Brazil that possess a Company Working Allowance permit. 
Highly novel or high risk devices will require the submission of an Economic Information Report 
assessing the impact the new device could possibly have in Brazil. All electrical devices must obtain 
INMETRO Certification, although this does not need to be done within Brazil, it is the only nation 
we observed that had such a requirement. Proof of compliance with the Brazilian Goods 
Manufacturing Practice must also be demonstrated and is subject to inspections every two years. 
With these preliminary steps completed, the Registration Holder may then submit a technical file to 
ANVISA for approval. Once approved, ANVISA issues a device registration certificate and a letter 
of authorization, both these documents must then be registered at a Brazilian consulate. All 
certificates issued are valid for five years.  
Canada  
Medical device registration in Canada is handled by Health Canada’s Health Products and Food 
Branch. Like Australia, Canada has tailored their regulatory process to international standards and 
follows the European model whenever possible. First, an ISO13485:2003 Certificate must be 
acquired. Approval for an ISO13485:2003 Certificate must be done by a CMDCAS accredited 
registrar. CMDCAS accreditation is managed by Health Canada and many European notified bodies 
possess CMDCAS accreditation. The ISO Certificate, Pre-Market Review documents, Medical 
Device License application, and relevant fees must then be sent to Health Canada for review and 
approval. Once approved the device is legal for sale in Canada subject to yearly approval fees.  
Once the aforementioned steps have been completed, the approved device is totally legal for sale in 
Canada. However, Canada operates under a nationalized healthcare system making the Canadian 
government itself the largest singular buyer of medical devices in the country. Due to the country’s 
huge landmass and relatively small population, using Health Canada as a distributor may be the 
easiest way to disseminate a new product across the country. In order to sell directly to the Canadian 
government, a Private Label Medical Device License must be acquired. This is a much faster process 
than normal device registration and is not subject to  
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yearly renewals. Depending on the level of interest, it is possible that Health Canada would purchase 
the rights to manufacture a PLMDL device within the country.  
China  
China purports a standardized regulatory process in compliance with most EU and US guidelines. In 
practice, approval in China can be substantially more difficult than most nations with standardized 
guidelines. First, a regulatory liaison, called a Legal Agent, and a distributor, called an After Sales 
Agent, must be appointed. Although the Legal and After Sales Agents are involved in the preparation 
and submission of documents, the device manufacturer is responsible for holding all of the necessary 
forms. A Registration Standard document must be prepared and submitted along with a prototype for 
type testing. Officially, a response for the SFDA should take no longer than two to three months but 
depending on the novelty of the device, it is entirely possible that it will be held longer causing an 
unknown amount of delay in registration. The results of type testing may result in the requirement of 
additional clinical trials to be held in China. If not needed, quality assurance documents may be 
submitted (ISO13485 Certificate or FDA equivalent, CE Mark or FDA Letter of Approval, etc.) 
along with technical files for approval. If successful, an Import Medical Device Registration 
Certificate is issued and is valid for four years.  
India  
India’s regulatory body does not classify devices via the tier system used in most of the rest of the 
world. Instead, devices in India are only subject to certain regulatory processes if they fall into one of 
the specific device listings. These listings do not include invasive medical devices and are more 
analogous to class II devices. Instead, regulatory approval relies on the appointment of a regulatory 
liaison and the completion of two forms. The regulatory liaison, called the India Authorized Agent, 
must be an Indian born national with five years’ experience in the given field (in this case, an 
electrophysiologist). The agent must also hold a valid Indian wholesale license, called Forms 20B 
and 21B. Through the agent, a device registration form must be submitted called Form 40. This form 
will require clinical data and approval data from the US, EU, Japan, or Australia is sufficient. Once 
approved the Indian governing body (CDSCO) will issue Certificate 41. Upon approval, an import 
license, called Form 10, will also need to be acquired. This import license specifies your in-country 
distributor and is held (along  
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with Certificate 41) by the India Authorized Agent. All forms are valid for three years and 
resubmission of forms is needed for continued approval.  
India is currently implementing a more complex and more defined regulatory system for medical 
devices. Presently, medical device registration can take place in under a year when approached with 
clinical data already in hand. However, distribution can be difficult outside major cities as India is a 
large, highly diverse, and regional country. Care must be taken during the registration process as 
changing distributors is a difficult process.  
South Korea  
Companies without a presence in South Korea must appoint a Korean License holder to submit and 
utilize the necessary certificates for registration in the country. The License Holder in Korea is 
different from many other nations in that it is the device distributors rather than manufacturers that 
must hold the license, and licenses are valid for entire categories of medical products, not individual 
patents. The largest effect on regulatory approval is the importance of choosing the correct distributor 
before entering the market, otherwise the regulatory process must be repeated to gain access to 
another distributor. While South Korea requires the standard ISO 13485 QMS compliance and the 
submission of a technical file, the standardized SER Technical File may be used in this submission. 
The submission of a technical file will also require the submission of a prototype for type testing by 
the KFDA. Successful completion of these submissions will result in a product license issued. Once 
the product license is obtained the Korean License Holder must then apply for a KGMP Certificate. 
This Certificate is effectively a yearly audit on the distributor and proof that they hold both a 
business license and relevant product license. All three of these documents must be presented by the 
Korean License Holder when importing products into the country.  
Russia  
Regulatory approval in Russia is managed by the Rozsdravnadzor and is designed to specifically 
separate itself from Europe. Unlike most approval processes which can rely on a variety of safety 
guarantees like quality systems, cite inspection, and post-market surveillance, Russian regulatory 
approval is dependent upon product testing to ensure safety. A company must be appointed to act as 
a regulatory liaison within Russia. Once appointed the regulatory liaison seeks out permission to 
import testing samples into the country. Testing must be conducted at  
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authorized expertise centers and hospitals within Russia. Using the data gathered in the quality, 
safety, and efficacy testing, a registration dossier must be compiled and submitted to the 
Rozsdravnadzor. Applicants may be requested to collect additional clinical data or proof of home-
country approval (although this appears to not be required, the Rozsdravnadzor reserves the right to 
request home-country approval before allowing the device into Russia). If approved, a GOST-R 
Certificate is issued which is valid for one year.  
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Results  
Sizing Up Markets and Difficulty of Regulatory Access  
Comparing the benefit of accessing a particular market against the difficulty of accessing that 
particular market can be difficult. There exists no metric that accurately defines the number of 
arrhythmia patients that we would gain by going into a specific country, so other derivatives must be 
considered. We initially organized ideal countries by those that theoretically had the largest number 
of potential arrhythmia sufferers. This made the countries with the oldest populations the most 
desirable but they all had difficult and involved approval processes (US, EU, Japan). As discussed 
earlier, the costs associated with pursuing approval in these three areas at once was not feasible.  
Instead of following the pathology of arrhythmia, we settled on a more concrete measurement, the 
annual amount spent on medical devices in a given country. This figure provided a more accurate 
look into what we could expect from gaining access to a particular country. Once again the US, EU, 
and Japan were at the top comprising over 75 % of the total market, but other nations can more 
readily be compared against one another. For example, Australia and Brazil, who possess similar age 
spreads and have nearly identical annual expenditures on medical devices, despite Brazil having 
nearly five times the population and four times the reported instances of arrhythmia compared to 
Australia. This data indicates that a countries economic status should have the most influence on 
whether or not it should be pursued as a market. Market size and regulatory ease do not necessarily 
make a country an ideal location. One such example would be India, despite its loose regulatory 
structure and 1.2 billion population, accounts for less than a 0.25% of the worldwide medical device 
market, making it a smaller market than Singapore. In fact, large and highly regionalized countries 
such as Brazil, India, Russia, and China have only recently begun controlling or enforcing medical 
device registration in the past 20 to 30 years. This has hindered their ability to buy devices 
internationally and often indicates that the regulatory system in place is undergoing constant changes.  
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Easy Access  
Many nations not initially considered or eliminated during the market review may also be worth 
pursuing after acquiring a CE Mark. These small nations often have a high per capita income, large 
annual expenditure on medical devices, and adhere to GHTF or European guidelines for clinical data. 
The timeline for approval in these countries is usually on the order of weeks to months, rather than 
years. Many of these nations rival smaller European nations in market size and incur similar 
registration costs.  
Singapore possesses a regulatory process that follows GHTF guidelines. Singapore device 
registration requires a regulatory liaison and clinical data. Hong Kong follows a similar process, with 
a registration time of two months. Malaysia does not require registration of a medical device, so 
access to Malaysia is gained by appointing a local distributor and going through the necessary forms 
to import a product. Israel, which was initially eliminated due to insufficient market data, grants 
approval to any existing device with an FDA Letter of Approval or CE Mark. Additional nations 
which rely heavily on medical device imports and have relatively simple regulatory processes include 
Columbia, Costa Rica, and the Philippines.  
Following International Standards  
In the present day, the European CE Mark has become the international standard for medical device 
registration throughout most of the world. The CE Mark has gained this status as it is the easiest to 
obtain of the three major standards most often used internationally. This means that subsequent 
regulatory approvals should be sought out in the countries that most recognize the CE Mark first. In 
our analysis, the three countries which most adhere to the European guidelines are Australia, Canada, 
and South Korea in that order. It is highly likely that a device as novel as the Circumblator will be 
required to perform multi-locational clinical trials and we recommend attempting to use trial cites in 
Australia and Canada when seeking a CE Mark if at all possible. Gaining access to South Korea is 
theoretically as easy as gaining access to Canada with a CE Mark but language and cultural barriers 
must be considered as well. Based on this, we recommend that approval in Australia, Canada, and 
South Korea be pursued either concurrently with European approval or immediately following CE 
Certification. Afterward, approval in Brazil and India may be worth considering as they represent 
some of the largest remaining markets but pose difficult distribution problems. Based on the need for 
type testing, distribution  
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issues, and bad international reputations we cannot recommend pursuing regulatory approval in the 
Russian Federation or Peoples Republic of China.  
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Discussion  
Our initial analysis favoring European CE Marking over alternative major approval routes was not 
surprising. The CE Mark is designed to get products to market safely in as short a time as possible 
and must be lose enough to work within the frameworks of the regulatory processes of its 30 member 
nations. The US and Japan place a higher importance on quality control and (theoretically) safety 
when compared to the free trade-based approach of the CE Mark. Initially, we knew that Automated 
Medical Instruments would be pursuing European approval first and the reasons became increasingly 
clear when compared to the other two regional powers.  
Regional influence also appears to play a larger role in international medical device markets. There is 
no international standard, the UN has not attempted to outline one, and the Global Harmonization 
Task Force is not an official body recognized by any government agency. The GHTF actually divides 
their guidelines along geographic regions (Europe, South East Asia, and the Americas) which hint 
that regional hegemonies have a larger influence over the regulatory process in a small nation than 
any notion of an international standard. Certainly this is true in many Latin American nations, which 
are more likely to have a system based on the FDA registration process. This could include the actual 
application process itself, using unique quality management standards instead of ISO 13485, or 
manifest itself in the form of random site inspections, reliance on testing, etc. The CE Mark is only 
applicable to countries lying within the EFTA, but many EU member-candidates have adopted 
guidelines that better follow CE directives. Many nations within the CEFTA (Macedonia, 
Montenegro, Serbia) may effectively be considered countries in which a CE Mark is a sufficient 
mark of quality to pursue registration. South East Asia appears to be the least reliant on any one 
nation from which regulatory processes are based. In fact, many South East Asian nations are turning 
to the European model to more readily gain access to new technologies as they hit the market. South 
Korea leads as having already adopted many CE directives, but a host of smaller nations, particularly 
those where medical tourism is popular, have streamlined registrations that accept approvals from 
most other countries.  
While no true international standard exists, countries are increasingly gravitating to a more 
standardized regulatory approach. Most often this results in using the CE Mark as a  
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guideline. Countries which did not regulate or enforce medical device guidelines until recently are 
frequently reviewing the registration process and new iterations increasingly resemble an existing 
major standard. India’s new proposed device classifications greatly resemble Europe’s. Countries 
that still possess minor testing requirements can often have that testing done through a notified body 
(such as Brazil’s INMETRO Certification or South Korea’s type testing).  
Overall, access to a majority of markets cannot be done at once. The US and Japan comprise over 
50% of all medical device purchases and each requires their own lengthy approval process regardless 
of the status of the device elsewhere. Economic status of a nation is the largest indicator of market 
size, with wealthy nations investing orders of magnitude more on medical devices per capita than 
poorer nations. This makes the path after acquiring a CE Mark direct. Approval should be sought in 
Australia and Canada either concurrently with European approval or immediately following it. From 
there, South Korea is the largest remaining market with a CE compliant regulatory process. Large 
and relatively poor nations pose distribution problems and have proven to be relatively small markets 
despite their population or size, for this reason we cannot recommend initially pursuing approval in 
countries like India and Brazil. Small wealthy nations make up a much larger share of the medical 
device market than initially suspected and for this reason we suggest looking into approval in 
Singapore, Hong Kong, and Israel following South Korean approval. Nearly all regulatory processes 
require some kind of post-market surveillance following approval and seeking approval in a country 
that requires additional testing often fulfills this requirement. Automated Medical Instruments can 
maintain continued CE Mark approval by conducting clinical trials in the US and submitting this 
information with the reapplication.  
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Appendix  
Glossary of Terms  
Competent authority – Any governmental regulatory agency responsible for the registration of 
medical products within that country. Most often refers to device registration in European countries 
after obtaining a CE Mark.  
EFTA – The European Free Trade Association is the area in which CE Mark directives apply. 
Includes the EU and neighboring Norway, Switzerland, Lichtenstein, and Iceland.  
GHTF – The Global Harmonization Taskforce is a voluntary organization of medical professionals 
that promote am international unified approach to medical product registrations.  
ISO – International organization for Standardization, international guidelines for nation’s regulatory 
processes. ISO 13485 and 14155 are the most commonly adhered to guidelines.  
ISO 13485:2003 Certification: A widely accepted certificate demonstrating compliance with the 
quality management systems outlined in ISO13485. Accepted in nearly every nation.  
Notified body – Third party authorized to issue a CE Mark by the EU. May also be qualified to carry 
out other certifications (such as Brazilian INMETRO certification).  
QMS - The organizational structure, procedures, processes and resources needed to ensure consistent 
performance in manufacturing. Proof of sufficient quality management systems is required in all 
regulatory process and is usually fulfilled by ISO standards.  
Regulatory Liaison – A person or company responsible for handling regulatory and sometimes 
distribution of a device in a country you are not based in. Requirements, importance, and legal 
capabilities for a liaison vary greatly by country.  
STED Documentation – Suggested standardized technical file documentation promoted by the 
GHTF. Not universally adopted but frequently accepted in place of technical documentation.  
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Selected Market Data  
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Regulatory Costs and Timetables  
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Historic and Country Specific European Information  
Five Year 
Rise in 
Arrhythmia 
in European 
Nations 2007  
2008  2009  2010  2011  
Great 
Britain  
7300  12057  14005  14222  15078  
France  18227  22139  26050  28800  31175  
Germany  30202  39500  40000  42000  50000  
Russia  9022  11200  13384  14048  16380  
Ireland  1600  700  800  800  1000  
 
 
 
